Clinical Trial Update: AHCC® as Immune Modulator in Cancer Patients Treated With Immunotherapy [NA]

View source ↗

Summary

Clinical trial update assessing AHCC as an immune modulator in cancer patients treated with immunotherapy; the study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• AHCC (Active Hexose Correlated Compound)

Snippet

Sponsor: National Cheng-Kung University Hospital | Conditions: Liver Cancer, Hepatocellular Carcinoma | NA | Status: NOT_YET_RECRUITING